Anti-SARS-CoV-2 S-RBD IgG Antibody Responses after COVID-19 mRNA Vaccine in the Chronic Disorder of Consciousness: A Pilot Study
Objective: In the last year, a large amount of research has investigated the anti-spike protein receptor-binding domain (S-RBD) antibody responses in patients at high risk of developing severe acute respiratory syndrome because of COVID-19 infection. However, no data are available on the chronic dis...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/24/5830 |
| _version_ | 1797503475104350208 |
|---|---|
| author | Maria Elena Pugliese Riccardo Battaglia Antonio Cerasa Maria Girolama Raso Francesco Coschignano Angela Pagliuso Roberta Bruschetta Giovanni Pugliese Paolo Scola Paolo Tonin |
| author_facet | Maria Elena Pugliese Riccardo Battaglia Antonio Cerasa Maria Girolama Raso Francesco Coschignano Angela Pagliuso Roberta Bruschetta Giovanni Pugliese Paolo Scola Paolo Tonin |
| author_sort | Maria Elena Pugliese |
| collection | DOAJ |
| description | Objective: In the last year, a large amount of research has investigated the anti-spike protein receptor-binding domain (S-RBD) antibody responses in patients at high risk of developing severe acute respiratory syndrome because of COVID-19 infection. However, no data are available on the chronic disorder of consciousness (DOC). Methods: Here, we evaluated anti-S-RBD IgG levels after vaccination in chronic DOC patients compared with demographically matched healthy controls (HC) by indirect chemiluminescence immunoassay. All individuals completed a two-dose-cycle vaccination with Pfizer mRNA vaccine (BNT162b2), and antibody responses were evaluated at 30 and 180 days after the administration of the second dose of vaccination. Results: We compared 32 DOC patients with 34 demographically matched healthy controls. Both DOC and HC groups showed a similar antibody response at 30 days, whereas at follow-up (180 days) DOC patients were characterized by lower S-RBD IgG levels with respect to controls. Additional multiple regression analyses including demographical and clinical comorbidities as predictors revealed that age was the only factor associated with the decrease in S-RBD IgG levels at follow-up (180 days). Elderly individuals of both groups were characterized by a reduction in the antibody responses with respect to younger individuals. Conclusions: Our results show an efficacy seroconversion in DOC patients in the first period after vaccination, which significantly declines over time with respect to healthy controls. |
| first_indexed | 2024-03-10T03:51:13Z |
| format | Article |
| id | doaj.art-e15201d0464e46c2bfee846687d161f5 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T03:51:13Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-e15201d0464e46c2bfee846687d161f52023-11-23T08:56:51ZengMDPI AGJournal of Clinical Medicine2077-03832021-12-011024583010.3390/jcm10245830Anti-SARS-CoV-2 S-RBD IgG Antibody Responses after COVID-19 mRNA Vaccine in the Chronic Disorder of Consciousness: A Pilot StudyMaria Elena Pugliese0Riccardo Battaglia1Antonio Cerasa2Maria Girolama Raso3Francesco Coschignano4Angela Pagliuso5Roberta Bruschetta6Giovanni Pugliese7Paolo Scola8Paolo Tonin9Intensive Rehabilitation Unit, S’Anna Institute, 88900 Crotone, ItalyIntensive Rehabilitation Unit, S’Anna Institute, 88900 Crotone, ItalyIntensive Rehabilitation Unit, S’Anna Institute, 88900 Crotone, ItalyIntensive Rehabilitation Unit, S’Anna Institute, 88900 Crotone, ItalyIntensive Rehabilitation Unit, S’Anna Institute, 88900 Crotone, ItalyIntensive Rehabilitation Unit, S’Anna Institute, 88900 Crotone, ItalyInstitute for Biomedical Research and Innovation (IRIB), National Research Council of Italy, 98164 Messina, ItalyIntensive Rehabilitation Unit, S’Anna Institute, 88900 Crotone, ItalyIntensive Rehabilitation Unit, S’Anna Institute, 88900 Crotone, ItalyIntensive Rehabilitation Unit, S’Anna Institute, 88900 Crotone, ItalyObjective: In the last year, a large amount of research has investigated the anti-spike protein receptor-binding domain (S-RBD) antibody responses in patients at high risk of developing severe acute respiratory syndrome because of COVID-19 infection. However, no data are available on the chronic disorder of consciousness (DOC). Methods: Here, we evaluated anti-S-RBD IgG levels after vaccination in chronic DOC patients compared with demographically matched healthy controls (HC) by indirect chemiluminescence immunoassay. All individuals completed a two-dose-cycle vaccination with Pfizer mRNA vaccine (BNT162b2), and antibody responses were evaluated at 30 and 180 days after the administration of the second dose of vaccination. Results: We compared 32 DOC patients with 34 demographically matched healthy controls. Both DOC and HC groups showed a similar antibody response at 30 days, whereas at follow-up (180 days) DOC patients were characterized by lower S-RBD IgG levels with respect to controls. Additional multiple regression analyses including demographical and clinical comorbidities as predictors revealed that age was the only factor associated with the decrease in S-RBD IgG levels at follow-up (180 days). Elderly individuals of both groups were characterized by a reduction in the antibody responses with respect to younger individuals. Conclusions: Our results show an efficacy seroconversion in DOC patients in the first period after vaccination, which significantly declines over time with respect to healthy controls.https://www.mdpi.com/2077-0383/10/24/5830COVID-19disorder of consciousnessvaccinationantibody responses |
| spellingShingle | Maria Elena Pugliese Riccardo Battaglia Antonio Cerasa Maria Girolama Raso Francesco Coschignano Angela Pagliuso Roberta Bruschetta Giovanni Pugliese Paolo Scola Paolo Tonin Anti-SARS-CoV-2 S-RBD IgG Antibody Responses after COVID-19 mRNA Vaccine in the Chronic Disorder of Consciousness: A Pilot Study Journal of Clinical Medicine COVID-19 disorder of consciousness vaccination antibody responses |
| title | Anti-SARS-CoV-2 S-RBD IgG Antibody Responses after COVID-19 mRNA Vaccine in the Chronic Disorder of Consciousness: A Pilot Study |
| title_full | Anti-SARS-CoV-2 S-RBD IgG Antibody Responses after COVID-19 mRNA Vaccine in the Chronic Disorder of Consciousness: A Pilot Study |
| title_fullStr | Anti-SARS-CoV-2 S-RBD IgG Antibody Responses after COVID-19 mRNA Vaccine in the Chronic Disorder of Consciousness: A Pilot Study |
| title_full_unstemmed | Anti-SARS-CoV-2 S-RBD IgG Antibody Responses after COVID-19 mRNA Vaccine in the Chronic Disorder of Consciousness: A Pilot Study |
| title_short | Anti-SARS-CoV-2 S-RBD IgG Antibody Responses after COVID-19 mRNA Vaccine in the Chronic Disorder of Consciousness: A Pilot Study |
| title_sort | anti sars cov 2 s rbd igg antibody responses after covid 19 mrna vaccine in the chronic disorder of consciousness a pilot study |
| topic | COVID-19 disorder of consciousness vaccination antibody responses |
| url | https://www.mdpi.com/2077-0383/10/24/5830 |
| work_keys_str_mv | AT mariaelenapugliese antisarscov2srbdiggantibodyresponsesaftercovid19mrnavaccineinthechronicdisorderofconsciousnessapilotstudy AT riccardobattaglia antisarscov2srbdiggantibodyresponsesaftercovid19mrnavaccineinthechronicdisorderofconsciousnessapilotstudy AT antoniocerasa antisarscov2srbdiggantibodyresponsesaftercovid19mrnavaccineinthechronicdisorderofconsciousnessapilotstudy AT mariagirolamaraso antisarscov2srbdiggantibodyresponsesaftercovid19mrnavaccineinthechronicdisorderofconsciousnessapilotstudy AT francescocoschignano antisarscov2srbdiggantibodyresponsesaftercovid19mrnavaccineinthechronicdisorderofconsciousnessapilotstudy AT angelapagliuso antisarscov2srbdiggantibodyresponsesaftercovid19mrnavaccineinthechronicdisorderofconsciousnessapilotstudy AT robertabruschetta antisarscov2srbdiggantibodyresponsesaftercovid19mrnavaccineinthechronicdisorderofconsciousnessapilotstudy AT giovannipugliese antisarscov2srbdiggantibodyresponsesaftercovid19mrnavaccineinthechronicdisorderofconsciousnessapilotstudy AT paoloscola antisarscov2srbdiggantibodyresponsesaftercovid19mrnavaccineinthechronicdisorderofconsciousnessapilotstudy AT paolotonin antisarscov2srbdiggantibodyresponsesaftercovid19mrnavaccineinthechronicdisorderofconsciousnessapilotstudy |